Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Boston, Massachusetts

Cancer surgery and procedure trials in Boston, MA

52 cancer surgery and procedure studies are recruiting participants at sites in Boston as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 52 studies are recruiting at a site in Boston.
  • By phase: Phase 1 (6), Phase 1/2 (4), Phase 2 (16), Phase 3 (14), Phase 4 (1), No phase (8), Observational (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (32), government (17), industry (3).
  • By research area: Breast Cancer (16), Lymphoma (16), Lung Cancer (10), Melanoma (4), Pancreatic Cancer (3), Prostate Cancer (3).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 52). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372640 · updated
  2. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05422794 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT05564377 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Tufts Medical Center
    Registry record
    NCT06058377 · updated
  5. Distance-Based Exercise to Preserve Function and Prevent Disability

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07059884 · updated
  6. The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    University Hospital, Basel, Switzerland
    Study site
    Harvard Medical School
    Registry record
    NCT05890677 · updated
  7. Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07137416 · updated
  8. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Lung cancer studies recruiting in Boston

  1. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT04665739 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Beth Israel Deaconess Medical Center · Boston Medical Center · Dana-Farber Cancer Institute
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Tufts Medical Center
    Registry record
    NCT06096844 · updated
  4. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Massachusetts General Hospital Cancer Center
    Registry record
    NCT03191149 · updated
  5. Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    Registry record
    NCT02984761 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Boston

  1. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    Brigham and Women's Hospital · Dana-Farber Cancer Institute
    Registry record
    NCT05946213 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Melanoma studies recruiting in Boston

  1. Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06585410 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Boston, MA on ClinicalTrials.gov.

Lymphoma studies recruiting in Boston

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06317662 · updated
  2. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT04726241 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05675410 · updated
  5. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital Cancer Center · Tufts Medical Center
    Registry record
    NCT07215910 · updated
  6. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Beth Israel Deaconess Medical Center · Dana-Farber Cancer Institute
    Registry record
    NCT07321652 · updated
  7. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06124157 · updated
  8. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    DFCI/BWH Brigham and Women's Hospital
    Registry record
    NCT06059391 · updated
  9. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    • Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    Brigham and Women's Hospital
    Registry record
    NCT07020533 · updated
  10. GLORY: Glofit-GemOx With Liso-Cel For Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07711483 · updated
  11. Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07061951 · updated
  12. CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

    • Phase 1/2
    • From 12 months, up to 21 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT04870944 · updated
  13. Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06745076 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Boston, MA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Boston

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372614 · updated
  2. Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

    • Observational
    • Up to age 17
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    Boston Children's Hospital
    Registry record
    NCT06651580 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call